To evaluate the therapeutic effect of Mongolian traditional prescriptions on patients with chronic obstructive pulmonary disease (COPD), a total of 153 COPD patients at stable stage were recruited, among which 94 patients were treated with budesonide, formoterol or indacaterol (western medicine group), and 59 patients were given additional Agari, Zandan-20, Qingfeirunze pill, etc. (Mongolian medicine group). After three months treatment, there was no significant difference in the pulmonary function indexes or six-minute walk test (6MWT) results between Mongolian and western medicine groups. There were significant differences in symptom score of Saint George's respiratory questionnaire (SGRQ) between the two groups (Adjusted P= 0.021). Compared with the baseline, the chronic obstructive pulmonary disease assessment test (CAT) score of the Mongolian medicine group decreased by 6 points, which was significantly higher than that of the western medicine group (Adjusted P< 0.001). For the CAT score, the proportions of patients decreased by 2 points or more, and the ratio of treated patients with lower or constant CAT score in the Mongolian medicine group were significantly higher than those in the western medicine group (P△CAT≤-2=0.001, corrected Pdecreased/fixed number=0.035). The disease impact score of SQGR decreased by 11.19 points in the Mongolian medicine group and 6.98 points in the western medicine group. The score of the Mongolian medicine group was significantly higher than that in the western medicine group (P=0.014). It was confirmed that the Mongolian medicine combined prescription can significantly improve respiratory symptoms, elevating the cardiopulmonary function.
[1] Higbee D H, Granell R, Smith G D, et al. Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry:A UK Biobank cohort analysis[J]. Lancet Respiratory Medicine, 2022, 10(2):149-157.
[2] Wang C X, Zhou J D, Wang J Q, et al. Progress in the mechanism and targeted drug therapy for COPD[J]. Signal Transduction and Targeted Therapy, 2020, 5(1):248.
[3] 苗青.中蒙医基础理论比较研究[D].济南:山东中医药大学中医学院, 2021.
[4] 肖莺鸽,李英格,刘锦文,等.蒙西医结合治疗慢性阻塞性肺疾病研究进展[J].中国民族医药杂志, 2018, 24(8):63-65.
[5] Deng Y X, Zhong J, Liu Z J, et al. Active ingredients targeting Nrf2 in the Mongolian medicine Qiwei Putao powder:Systematic pharmacological prediction and validation for chronic obstructive pulmonary disease treatment[J]. Journal of Ethnopharmacology, 2021, 265:113385.
[6] Ji L C, Yin J F, Lu C R, et al. Control of chronic obstructive pulmonary disease in urban populations:Findings from a cross-sectional prevalence survey in Shenzhen, China[J]. Environmental Science and Pollution Research International, 2022, 29(8):11843-11853.
[7] Xu J, Wang X D, Li Z H, et al. AECOPD research in the past ten years:A bibliographic analysis based on Web of Science[J]. Annals of Palliative Medicine, 2021, 10(10):10401-10413.
[8] Liu S, Zhou Y M, Liu S X, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease:Results from a cross-sectional study in China[J]. Thorax, 2017, 72(9):788-795.
[9] 朱蕾,陈荣昌.成人肺功能诊断规范中国专家共识[J].临床肺科杂志, 2022, 27(7):973-981.
[10] Zhou Z J, Zhou A Y, Zhao Y Y, et al. Evaluating the clinical COPD questionnaire:A systematic review[J]. Respirology, 2017, 22(2):251-262.
[11] 董毅峰,董超峰,董丹,等.试述蒙医学特色理论三要素学说[J].中国民族医药杂志, 2015, 21(9):31-33.
[12] 常虹,张春红,张娜,等.中药药性理论研究方法对蒙古族药药性理论研究的启示与借鉴[J].中草药, 2021, 52(23):7364-7372.
[13] 吉小平,阿丽沙,于红珍,等.蒙药方剂配伍研究概况[J].中国民族民间医药, 2021, 30(2):55-58.
[14] 银龙,青玉,李英格.蒙药阿嘎如-15味散治疗慢性支气管炎32例[J].中国中医药科技, 2016, 23(3):361-362.
[15] 马牡兰,贺希叶乐吐.蒙西药结合治疗支气管哮喘的临床观察[J].中国民族医药杂志, 2020, 26(11):1-2.
[16] 特门巴雅尔,都格尔.蒙药治疗慢性支气管哮喘68例疗效观察[J].中国民族医药杂志, 2018, 24(7):19.
[17] 浩斯其木格.蒙药阿嘎如-15味散治疗小儿毛细支气管炎的可行性及有效性观察[J].临床医药文献电子杂志, 2020, 7(50):136-137.
[18] 布仁巴图,巴图德力根,崔国军,等.清肺润泽丸联合化疗治疗继发型肺结核临床观察[J].中药药理与临床, 2013, 29(6):155-159.
[19] 夏瑶宾,朱明,赵秀清.《中华人民共和国卫生部药品标准》蒙药分册质量标准研究概况[J].中国民族医药杂志, 2006, 12(1):44-45.
[20] Zeng G S, Chen L C, Fan H Z, et al. The relationship between steps of 6MWT and COPD severity:A crosssectional study[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2019, 14:141-148.
[21] Kakavas S, Kotsiou O S, Perlikos F, et al. Pulmonary function testing in COPD:Looking beyond the curtain of FEV1[J]. NPJ Primary Care Respiratory Medicine, 2021, 31(1):23.
[22] Sousa S R, Caldeira J N, Rodrigues C, et al. Lung cancer screening in clinical practice:identification of highrisk chronic obstructive pulmonary disease patients[J]. Revista da Associaçaõ Médica Brasileira, 2022, 68(4):502-506.
[23] Gülhan P Y, Arbak P M, Annakkaya A N, et al. An assessment of post-COVID-19 infection pulmonary functions in healthcare professionals[J]. American Journal of Infection Control, 2022, 50(10):1125-1132.
[24] Zou R H, Bon J. Reduced Dlco in GOLD I COPD:Moving towards a multidimensional approach to risk stratification[J]. Chest, 2021, 160(3):791-792.
[25] Zikyri A, Pastaka C, Gourgoulianis K I. Hypercapnic COPD patients and NIV at home:Is there any benefit?Using the CAT and BODE index in an effort to prove benefits of NIV in these patients[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2018, 13:2191-2198.
[26] Choi J, Oh J Y, Lee Y S, et al. The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2019, 14:953-959.
